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ABSTRACT
Infection with enterotoxigenic Escherichia coli (ETEC) is an important cause of diarrhea-related illness and
death among children under 5 years of age in low– and middle-income countries (LMIC). Recent studies
have found that it is the ETEC subtypes that produce the heat-stable enterotoxin (ST), irrespective of
whether they also secrete the heat-labile enterotoxin (LT), which contribute most importantly to the
disease burden in children from LMIC. Therefore, adding an ST toxoid would importantly complement
ongoing ETEC vaccine development efforts. The ST’s potent toxicity, its structural similarity to the
endogenous peptides guanylin and uroguanylin, and its poor immunogenicity have all complicated
the advancement of ST-based vaccine development. Recent remarkable progress, however, including
the unprecedented screening for optimal ST mutants, mapping of cross-reacting ST epitopes and
improved ST-carrier coupling strategies (bioconjugation and genetic fusion), enables the rational design
of safe, immunogenic, and well-defined ST-based vaccine candidates.
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Infection with enterotoxigenic Escherichia coli (ETEC) is one of
the major causes of diarrhea-related illness and death among
children under 5 years of age in low- and middle-income coun-
tries (LMIC).1–3 These very common infections are estimated to
cause some 25,000 child deaths annually and contribute to child
malnutrition.1 Besides, ETEC is the leading cause of diarrhea
among tourists4,5 and military personnel6,7 staying in ETEC
endemic regions. Deaths associated with ETEC infection are
declining worldwide; nevertheless, morbidity remains high.1
Notably, children who survive repeated diarrheal episodes have
a higher risk of long-term sequelae, including impaired cognitive
development, growth faltering, and obesity.8 Collectively, these
short and long-term negative impacts of ETEC infection under-
line the need for effective interventions.
Protection against ETEC colonization and diarrhea
through the use of effective vaccines appears to be the most
promising way forward.2 There are, however, no effective
vaccines against ETEC at present. Currently, multiple efforts,
including the development of whole-cell and subunit vaccines,
are underway to develop a broadly protective ETEC vaccine.9
The more advanced candidates include the inactivated whole-
cell (ETVAX)10 and the live-attenuated ACE52711 vaccines.
Recent studies confirm our earlier work12 that ETEC strains
producing the heat-stable enterotoxin (ST), with or without
the heat-labile enterotoxin (LT), are strongly associated with
diarrhea among children under 5 years of age,3,13 while the
strains that only produce LT contribute only marginally. This
underpins the importance of including an ST toxoid in
vaccine formulations to achieve a broad protection against
ETEC.9 Herein, we review the recent advances in ETEC sub-
unit vaccine development, with an emphasis on the
approaches that target ST.
Mechanisms of human ETEC-mediated diarrhea
Human ETEC is comprised of genetically diverse stains,14 but
they share the ability to colonize the small intestine where
they secrete the plasmid-encoded ST and/or LT. Either of
these potent toxins can cause diarrhea individually, but
when present together, they appear to act synergistically.15
Following an infection through the fecal-oral route, ETEC
utilizes surface exposed adhesins, called colonization factors
(CFs), to colonize the small intestine and elaborate the toxins.
The CFs consist of repeating protein subunits and can be
fimbrial, helical or fibrillary structures.16
LT is a heterohexameric protein containing one A subunit
(LTA) and five identical B subunits (LTB), and it is structu-
rally and functionally related to the cholera toxin.17 ST exist
in two nearly identical variants, STa I and STa II, which are
commonly called STp (18 amino acids) and STh (19 amino
acids), where p and h refer to their initial discovery in ETEC
isolated from pigs and humans, respectively.18 While ETEC
producing either STh or STp can induce diarrhea in
humans,12,19,20 the STh-producers contribute with the bulk
of the diarrheal disease burden in LMIC children.12,21 ST
and LT induce diarrhea by binding to their cognate recep-
tors, the transmembrane guanylate cyclase C (GC-C) and
GM1-ganglioside on the epithelial cell surface, respectively,
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thereby triggering a cascade of signaling pathways that dis-
rupt the electrolyte and fluid homeostasis, ultimately leading
to secretion of water and electrolytes into the intestinal
lumen. While GM1 is the primary receptor for LT, second-
ary receptors, including blood group antigens, Toll-like
receptor 2 and additional gangliosides or ganglioside deriva-
tives have been reported.22,23 Guanylin and uroguanylin are
endogenous ligands that act on GC-C to regulate fluid and
electrolyte secretion into the intestinal lumen. Interestingly,
ST also appears to modulate the immune system of the host,
thereby preventing a strong immune response against the
infection.15 Likewise, exposure to LT has been shown to
downregulate expression of human antimicrobial peptides.24
Structure and function of the GC-C receptor ligands
The ETEC heat-stable toxins were discovered already in the
1970s25 and shown to cause increased levels of cGMP in
intestinal cells.26 In 1990, the GC-C receptor was shown to
be responsible for the ST-induced increased levels of intracel-
lular cGMP,27 and a few years later the endogenous peptides
guanylin28 and uroguanylin29 were discovered.
GC-C is a heavily glycosylated transmembrane protein
consisting of an extracellular receptor domain (ECD), a single
transmembrane helix, a kinase homology domain, and a cat-
alytic GC domain.18,30 Although the structure of GC-C has
not been solved, homology modeling suggests that the recep-
tor may form oligomers and that the membrane-proximal
subdomain of ECD appears to contain the binding site for
ST and the endogenous ligands.18,31,32 An additional receptor
for guanylin and uroguanylin has been identified, namely GC-
D, which is exclusively expressed in olfactory neurons.33,34 In
kidneys, however, guanylin and uroguanylin act primarily
through GC-C independent receptors that are not yet
identified.35
The structure of a fully toxic truncated synthetic STp
analog, where C5 was substituted with β-mercaptopropionic
acid, was solved by X-ray crystallography in 1991.36 The STp
analog covers the 13-amino acid toxic domain, from the first
(C5) to the last (C17) cysteine residues. The solution struc-
tures of guanylin37 and uroguanylin38 were solved later by
NMR, demonstrating striking structural similarities to each
other and to STp (Figure 1A). These three experimental
structures were used as templates to build structural models
for the full-length STp and STh peptides39 (Figure 1A), which
are useful when comparing the structural properties of the
four GC-C ligand peptides. The guanylin and uroguanylin
peptides have two disulfide bridges that define their structures
(1−3/2−4 pattern, Figure 1B). Interestingly, these peptides can
form two topological isomers that can dynamically
interconvert.37,38 Isomer A of guanylin and uroguanylin are
biologically active and their structures resemble those of the
Figure 1. Structural models and sequence alignment of STp, STh, uroguanylin and guanylin. A) Surface (top) and cartoon (bottom) representation of structural
models of STp39 and STh39 and NMR structures of uroguanylin (PDB accession no. 1UYA) and guanylin (PDB accession no. 1GNA). Each residue is named using the
one-letter amino acid code and numbered according to the individual peptide sequence. The first two N-terminal residues in guanylin are largely unstructured in
solution, and thus only the structure of the 13 C-terminal residues was solved by NMR.37 The disulfide bridge-forming cysteines are shown in yellow, and other
residues shared between at least three of the peptides are shown in blue. In the cartoon representation, the disulfide bridges are shown as sticks with sulfur atoms in
yellow. The receptor-interacting residues of the ST peptides, and the equivalent residues of uroguanylin and guanylin, are also shown as sticks with oxygen atoms in
red and nitrogen atoms in dark blue. B) Sequence alignment of STp, STh, uroguanylin, and guanylin. The residues are colored as described for the structures:
cysteines in yellow and residues shared between at least three peptides in blue. The disulfide bridge connectivity for STp and STh is shown above the alignment, and
that of uroguanylin and guanylin is shown below. Note that all peptides share two of the disulfide bridges. The receptor-interacting residues are marked with
asterisks, and the residue numbers of STh are shown below the STh sequence. Sequence identity (percentage) relative to STh is shown to the right of the alignment.
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ST peptides (Figure 1A). Isomer B, on the other hand, are
unable to activate the GC-C receptor. The ST peptides share
the two disulfide bridges of the endogenous peptides (2–5/3–6
pattern, Figure 1B), but has an additional disulfide bridge (1–
4 pattern, Figure 1B) which apparently locks the ST structures
in the active topological from and may explain why ST has a
higher affinity to the GC-C receptor than the endogenous
peptides.18,40,41
The structural similarities between the four peptides are
also reflected in their sequences (Figure 1B). STh and STp are
very similar and share 13 of their 19 and 18 residues, respec-
tively (78% sequence identity), and only one residue is differ-
ent inside the toxic domain (STh: T16; STp: A15). The
endogenous peptide which is most similar to the ST peptides
is uroguanylin, which shares 11 residues with STh (69%
sequence identity). Guanylin is less similar but shares 8 resi-
dues with STh (53% sequence similarity).
There is no direct structural evidence of the interaction
between GC-C peptides and the GC-C receptor, but several
mutational studies performed in the 1990s and 2000s on STh
and STp have resulted in the identification of residues impor-
tant for function.42–44 These studies mainly targeted the resi-
dues N12, P13, and A14 (STh residue numbering is used here
and throughout the review), all of which appeared to be
important for the biological activity of the ST peptides, and
were labeled receptor-interacting residues. We recently pub-
lished the most comprehensive mutational study of STh to
date, where all possible 361 single amino acid substitutions of
STh were screened for effects on toxicity and antigenicity.45
This study confirmed the functional importance of N12, P13,
and A14, but additionally identified L9 as a novel receptor-
interacting residue (Figure 1A). The A14 residue has the most
compelling evidence for being directly involved in the inter-
action with the receptor, as 17 of 19 possible substitutions in
this position leads to dramatically reduced biological activity.-
45 Even the two least dramatic substitutions lead to around
10-fold reduction in biological activity,43,45 despite entailing
the minor changes of either removing the methyl side chain of
alanine (glycine mutation), or the addition of a hydroxyl
group to the alanine side chain (serine). The importance of
the A14 residue for a biological function is further corrobo-
rated by the fact that A14 is the only receptor-interacting
residue that is conserved in all four GC-C peptides (Figure 1).
With the exception of P13, all the receptor-interacting
residues identified in the ST peptides are shared with urogua-
nylin (Figure 1). Other residues that are shared between STh
and uroguanylin are E8, T16, G17, and the four cysteine
residues C7, C10, C15, and C18. The extent of shared residues
explains the observed immunological cross-reaction between
anti-STh antibodies and uroguanylin,39,45 and underpins the
importance of addressing unwanted immunological cross-
reaction when constructing and evaluating vaccine candidate
ST toxoids.
Recent updates on CF-based ETEC subunit vaccine
development
Subunit vaccines have the potential of allowing the devel-
opment of safe and well-defined vaccines containing only
the desired antigens leading to targeted immune responses
towards specific epitopes.46 They further allow exclusion
of parts of antigens that may cause unwanted immunolo-
gical cross-reactions or allergenic and reactogenic
responses.46,47
In a response to infection with ETEC, the human body
normally elicits antibody responses against the CFs and
LT.48,49 Therefore, canonical approaches for ETEC vaccine
development have primarily been focused on engendering
protection against the CFs and LT.11,50,51 Unfortunately, CF-
and LT-based vaccines have not yet been shown to confer
adequate protection, even in travelers, in whom ETEC that
express only LT is indeed an important contributor to
diarrhea.51–53 As mentioned above, because such strains do
not contribute importantly to the diarrheal disease burden in
LMIC children, it is inappropriate to only aim for anti-LT
immunity. This challenge could be circumvented by engen-
dering immune responses to important somatic antigens on
ETEC strains that express STh. Thus, despite there being no
evidence that CFs induce anticolonizing immunity after nat-
ural ETEC infections,54 important efforts are being made to
develop a vaccine which induces immune responses against
the major CFs, i.e. those on ETEC that account for the bulk
of ETEC diarrheal disease burden. However, this vaccine
development strategy is complicated by the fact that human
ETEC may produce one or more of over 25 immunologically
distinct CFs,16 and it is likely that new CFs will be
discovered.14 Recently, some level of cross-protection was
reported.10
To overcome the challenges posed by the heterogeneity of
CF, recent subunit vaccine approaches have employed multi-
epitope fusion antigen (MEFA) technology to integrate epi-
topes from CFs that are produced by strains most commonly
found associated with moderate and severe diarrhea.55
Accordingly, in silico predicted B-cell epitopes from CFA/I,
CS1, CS2, CS3, CS4, CS5, CS6, CS21, and EtpA were inserted
into the backbone of the colonization factor antigen I (CFA/I)
tip subunit CfaE where they replaced surface exposed, but less
antigenic peptides.56 Notably, mice immunized with the chi-
meric antigen elicited antibodies against all the nine epitopes,
and the sera prevented the attachment of ETEC strains to
Caco-2 cells in vitro.56 MEFA CFs were further genetically
fused to an ST toxoid and LT antigen to afford even broader
protection.57,58 Immunized mice that were challenged with
lethal doses of ETEC (CFA/I+, LT+, ST+) were protected.58
Collectively, these results are encouraging, and future ETEC
challenge studies will determine whether multiepitope fusions
may provide broad protection against ETEC diarrhea in
humans.
Generally, a multivalent subunit vaccine that targets differ-
ent stages of the ETEC infection process, including mucin
degradation, adhesion and toxin neutralization, may lead to a
broadly protecting ETEC vaccine. In this regard, the recently
identified novel and fairly conserved protective antigens,
including YghJ, EtpA, EatA, EaeH, and flagellin59 could be
exploited for vaccine development, whilst evaluating the risk
that YghJ, EaeH and flagellin-based vaccines may pose to the
E. coli commensals, since these antigens are often also pro-
duced by commensal E. coli.
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Strategies for designing ST-based subunit vaccines
The ST amino acid sequences are highly conserved
(Figure 1B)60 and STh-producing ETEC, whether they also
produce LT or not, contribute to the bulk of diarrhea in LMIC
children.3,13,21 In addition, ETEC that produce STp and/or LT
contribute to diarrhea in travelers and may cause outbreaks.19
Taken together, this makes it important to also target ST
when developing a broadly protective ETEC vaccine.
Nonetheless, the poor immunogenicity of ST, its potent toxi-
city, and its potential for immunological cross-reactivity with
the human gastrointestinal peptides (guanylin and uroguany-
lin) have so far hampered the advancement of an ST-based
vaccine.39,42 The development of an ST-toxoid for inclusion in
a broadly protective ETEC vaccine thus needs to overcome
these three challenges, while ensuring that the ST toxoid
engenders antibodies that effectively neutralize STh, and pre-
ferably also STp.
Making ST immunogenic
Natural ETEC infections do not appear to induce an immune
response against ST. This is presumably due to the small size
of ST (~ 2 kDa) as small molecules called haptens (incomplete
antigens) are generally poor immunogens.61 To elicit anti-ST
antibodies, ST has commonly been coupled to an immuno-
genic protein (carrier protein) through chemical crosslinking
(bioconjugation)62,63 or genetic fusion.64 Both approaches
have been effective in eliciting antibodies against ST. Efforts
have also been made to develop ST-based vaccines without
using carrier proteins. Encouraging results have emerged
from experiments with ST polymerization using
glutaraldehyde,65,66 ST coupled to a poly lactic-co-glycolic
acid (PLGA) nanoparticle,67 and ST coupled to a lipopeptide
module (T-helper cell epitope and S-[2,3-bis (palmitoyloxy)
propyl] cysteine).68
Abolishing ST toxicity
ST’s toxicity is significantly reduced or abolished when
conjugated63 or genetically fused69 to carrier proteins.
However, the reversibility of some conjugation reactions70 or
proteolytic activity71 in the vaccine recipients after oral deliv-
ery could potentially release the native toxin. Therefore,
detoxifying mutations are required to ensure a safe ST-based
vaccine. But due to its small size, ST has a limited repertoire
of epitopes, and mutations must be carefully chosen to avoid
disrupting protective epitopes or forming neo-epitopes.
Minimizing immunological cross-reactivity with guanylin
and uroguanylin
The endogenous peptides guanylin and uroguanylin play key
roles in regulating electrolytes and fluid homeostasis in the
human intestine via GC-C, which is the primary receptor for
guanylin and uroguanylin.27,72 Although GC-C is predomi-
nantly expressed in the intestines,73 transcripts have also been
detected in kidneys, adrenal gland, brain, lung and reproduc-
tive organs,33,34,74,75 suggesting crucial roles played by the
GC-C ligands in the human physiology. Recently, there is a
renewed interest in these peptide hormones as potential ther-
apeutic targets for obesity, ulcerative colitis, and metabolic
diseases.75–77
Given their key roles in human physiology, their resem-
blance to ST (Figure 1A) raises a safety concern that anti-ST
antibodies elicited by ST-based vaccines may cross-react with
these endogenous peptides. Indeed, it has already been shown
that anti-STh antibodies can cross-react with uroguanylin,
albeit only partially and with lower affinity.39 Hence, one or
more mutations may also be needed to minimize the risk of
engendering antibodies that cross-react with the endogenous
ligands.
In the following, we review recent efforts to address the
three challenges, focusing on two strategies for making ST
immunogenic by coupling it to a protein carrier, and on
abolishing toxicity and reducing the risk for unwanted immu-
nological cross-reaction by mutation.
Making ST immunogenic by coupling it to a protein
carrier
Protein carriers provide the epitopes needed for recognition
by T-helper cells in genetic fusions or chemical conjugates,
thereby enabling the induction of high-affinity antibodies and
immune memory also to peptide haptens.46,78 Carrier proteins
to which ST has been coupled include the porcine immuno-
globulin G, bovine serum albumin (BSA), cholera toxin B
(CT-B), outer membrane OmpC, major subunit ClpG of E.
coli CS31A fimbriae, Salmonella flagellin, and green fluores-
cent protein.42,79,80 In addition, LT and LT derivatives have
been widely used with the rationale that broad protection can
be achieved against ETEC strains producing either or both
enterotoxins.62,63,69,81,82 To provide a more comprehensive
protection, an ST toxoid-LTB fusion has further been geneti-
cally fused to ETEC CF antigens or epitopes that elicit anti-
adhesin antibodies.57,58 The non-toxic double mutant LT
(dmLT; LTR192G/L211A) has also been used as a carrier, offering
the additional benefit of engendering neutralizing anti-LT
antibodies.83–85 Additionally, an LT-SThP13F fusion was incor-
porated into a live attenuated oral E. coli vaccine (ZCR533)
that constitutively express the antigen on its surface or as a
secretion.86
ST-carrier genetic fusion
The finding that native ST genetically fused with a carrier
protein such as LT could elicit anti-ST neutralizing antibodies
was first made in the 1980s.87 A genetic fusion of an ST toxoid
and LTB coupled to a gelatin nanoparticle was shown to
protect mice when experimentally infected with ETEC.88
Genetic fusion approaches to ST-based vaccine development
has, therefore, been an important strategy for developing ST
toxoid-based ETEC vaccines.57,81,89–92 Three copies of an
STh-N12S mutant genetically fused with dmLT, 3xSThN12S-
dmLT, was identified as a promising vaccine candidate that
may engender neutralizing antibodies against both ST and
LT.84,85,92 Notably, piglets born from 3xSThN12S-dmLT
immunized pregnant gilts seemed to be passively protected
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from ETEC diarrhea during challenge.85 The 3xSThN12S-
dmLT construct was further genetically fused to seven puta-
tive immunodominant colonization factor epitopes from pre-
valent ETEC strains (CFA/I/II/IV).57 Interestingly, the
expressed single polypeptide immunogen elicited anti-adhesin
antibodies against all the seven CFA in addition to anti-ST
and anti-LT antibodies in mice.57,93 The related adhesin-tox-
oid MEFA (CFA/I/II/IV-3xSThN12S-mnLTG192G/L211A) con-
taining epitopes of seven CF adhesins, three copies of STh
toxoid and a monomeric LT mutant is currently among the
leading ETEC subunit candidates in the preclinical phases,93
and it remains to be seen whether it can elicit an active
protective response in animal and human challenge studies.
The abovementioned recently developed ST fusion con-
structs were expressed as inclusion bodies in the cytoplasm
of E. coli and subjected to a simple refolding protocol
(Novagen). To our knowledge, the refolded immunogens
have not been characterized structurally, and hence, it
remains unclear to what extent the individual ST copies
have correctly formed disulfide bridges and intact structures.
Despite the fact that these fusion immunogens seem to elicit
neutralizing anti-ST antibodies, one concern is to what extent
that different immunogen batches will have consistent bio-
physical properties.
ST-carrier bioconjugation
Making ST immunogenic by chemically conjugating it to a
protein carrier has two advantages over genetic fusion. The
first is that the ST peptides (both native and mutants) can be
made either recombinantly or by chemical synthesis,94 and
subsequently be subjected to thorough biophysical character-
izations to ensure that protective epitopes are intact. This is
important because ST contains conformational epitopes.95,96
The second advantage is that one can achieve much higher
hapten-to-carrier ratios with bioconjugation than genetic
fusions. This may be essential for eliciting strong and consis-
tent immune responses. The drawback compared to genetic
fusion is that the production procedure is more elaborate.
Chemical conjugation offers a plethora of options for mak-
ing conjugates. The choice of coupling chemistry will govern
the overall structure of the conjugate vaccine as well as how
ST epitopes are presented to the immune system. It is impor-
tant that the chosen coupling method leads to a well-defined
conjugate that elicits ST-specific neutralizing antibodies with
a high and consistent titer.
The most commonly used chemical crosslinkers for cou-
pling ST to carrier proteins have been the carbodiimides62,79,97
and glutaraldehyde.39,63,65 However, these crosslinkers pro-
mote polymerization, leading to poorly defined and higher
molecular weight conjugates that may eventually precipitate.98
An improved protocol that involves introducing carboxyl
groups on BSA and coupling ST through its N-terminus
using dicyclohexylcarbodiimide (DCC) crosslinker has been
reported.80 Alternatively, heterobifunctional crosslinkers
(containing different reactive groups on either end) used in
a two-step conjugation will allow one to tailor the molecular
orientation of ST on the carrier.98 Additional factors that need
to be considered for optimization include the solubility of the
resulting conjugate, spacer arm (affects flexibility and steric
hindrance), the potential for immunogenicity of the cross-
linker, and in vivo toxicity.99
The way ST is oriented on the carrier may have a profound
effect on the immune response to the conjugate. For example,
ST coupled to a lipopeptide module via N-terminus elicited
better neutralizing antibodies than when coupled via the
C-terminus.68 Likewise, a 19-amino acid peptide (verotoxin
2e) conjugated to ovalbumin through a central amino acid
gave higher antibody titers than when the peptide was
coupled via terminal residues.100 ST has three reactive groups
that can be used for conventional conjugation: the amino
group of the N-terminus, the carboxyl groups of the
C-terminus and the glutamic acid residue (E8), and the thiol
groups of the cysteines. However, the thiol groups should be
excluded to avoid disruption of the disulfide bridges. When
producing ST by chemical synthesis it is possible to block
certain reactive groups or to introduce non-natural amino
acids to enable conjugation through a targeted residue.101
Interestingly, linking ST with a lipopeptide module via an
oxime linkage generated antibodies with a better neutralizing
capacity than when thioether linkage was used68 suggesting
that the chemical nature of the linkage could also affect the
quality of the immune response to the toxoid.
As mentioned, bioconjugation allows for higher hapten-to-
carrier ratios than genetic fusion. However, although higher
ratios usually lead to higher antibody titers, it does not guar-
antee that the antibodies produced will have a higher affinity
to ST or be more capable of neutralizing ST. For instance, an
increasing ratio of verotoxin 2e to ovalbumin was found to
correlate with an increased antibody titer, but the affinity of
the antibodies became poorer.100 Therefore, the ST-to-carrier
ratio will require optimization for each vaccine design.
Mutating ST to abolish toxicity and reduce the risk of
unwanted immunological cross-reactions
Two safety concerns require that the native ST toxin is mod-
ified by mutation, namely to abolish toxicity and to reduce the
risk of eliciting antibodies that cross-react with the endogen-
ous peptides. As mentioned, the small size of ST implies that
it has a limited repertoire of epitopes, and that mutations
must be carefully chosen to avoid disrupting protective
epitopes.
In a recent screen of 14 single amino acid ST mutants
fused to a dmLT, STh-N12S, STh-N12T and STh-A14H
were identified as promising ST toxoids.92 The STh-N12S
seems to be the most promising one, and is the current lead
candidate mutation for the LT-based genetic fusions reviewed
above.84,85
In our mutational study of all possible 361 single-amino
acid substitutions of STh, where we screened for effects on
toxicity and antigenicity, the top 30 toxoid candidates (based
on their antigenicity-toxicity ratios) had mutations either in
L9, N12 or A14.45 Notably, 17 A14 mutation toxoids had
undetectable toxicities in the T84 cell assay,45 suggesting that
A14 is the prime residue to target for abolishing toxicity.
The screen further demonstrated that mutations of the
structurally important cysteine residues had a profound
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impact on both toxicity and antigenicity,45,102 and that muta-
tions of P13 also, but to a lesser extent, affected both toxicity
and antigenicity.45 Hence, to ensure the formation of ST
mutants with a correct structure and intact epitopes, these
residues should not be targeted for mutation.
The STh mutant library was also used to map the epitopes of
three neutralizing monoclonal antibodies.45 This led to two key
observations: that the L9 residue which is shared with urogua-
nylin is the main epitope residue of a cross-reacting anti-STh
monoclonal antibody and that the main epitope residue of two
non-cross-reacting anti-STp monoclonal antibodies was Y19.
This implies that L9 is an attractive residue to target for muta-
tion, resulting in mutant variants with both reduced toxicity and
risk for cross-reactions to the endogenous peptides. It also
implies that Y19 constitutes an ST-specific and safe epitope,
which should be left intact and exposed in a vaccine candidate
toxoid. This may also explain why ST coupled to a lipopeptide
module via the N-terminus elicited better neutralizing antibo-
dies than when coupled via the C-terminus.68
The single STh mutant, N12S, and two double mutants,
L9A/N12S, and N12S/A14T, were recently reported to elicit
neutralizing antibodies in mice that showed little immunolo-
gical cross-reactions to the endogenous peptides, when geneti-
cally fused in triplicate to monomeric-LTR192G/L211A.
91
However, when the authors assessed the immunological
cross-reactions using a competitive ST ELISA, the ratio
between free and bound peptide competing for binding to
antibody was kept constant, in contrast to our previously
published approach where we varied the ratio between free
and bound peptides.39 In our opinion, a proper dose-response
experiment must be conducted in order to convincingly
describe possible immunological cross-reactions or the lack
thereof. In addition, sera were pooled from six individual
mice prior to testing for both neutralization and cross-reac-
tions, which is unfortunate, as it may mask inter-individual
variations, which we have recently observed (Diaz et al.,
manuscript in preparation).
In conclusion, over the recent years considerable progress
has been made on making ST immunogenic, and on identify-
ing mutations that will reduce or abolish toxicity. But the
important challenge of demonstrating the reduction of
unwanted immunological cross-reactions to guanylin and
uroguanylin remains.
Concluding remarks and future perspectives
The lack of well-conserved antigens to formulate a broadly
protective vaccine has been the main challenge in ETEC vaccine
development. The heterogeneity of the CFs has so far posed a
practical challenge in formulating a CF-based ETEC vaccine
that targets the ETEC strains responsible for the bulk of ETEC
diarrhea. Recent ST toxoid-based ETEC subunit strategies out-
lined here are showing encouraging results that we believe may
importantly complement the CF- and LT-based approaches. We
expect that these efforts will soon result in ST toxoid candidates
that can be evaluated in clinical trials.
Meanwhile, the lack of a suitable animal model that reca-
pitulates ETEC mediated infection and diarrhea hinders the
screening of potential vaccine candidates at an early stage of
vaccine development. So far, mouse models are restricted to
studying the protective efficacy of antigens in ETEC
colonization103,104 and protection against lethal ETEC doses.58
Furthermore, human challenge models for evaluating the
protective efficacy of ETEC vaccines have so far focused on
strains that also produce LT.105,106 There is a need to develop
a human challenge model for ETEC that only express STh,
and important progress towards establishing such a model has
recently been made.107
Finally, since ETEC is an enteric pathogen, the ETEC
vaccine needs to primarily induce mucosal IgA responses. In
this respect, dmLT has shown promise as an adjuvant that
redirects parenterally administered vaccines to an immune
response in the gut.108
It is our hope that ongoing efforts to develop a safe and
immunogenic ST toxoid capable of inducing strong mucosal
immune responses in the human gut can importantly com-
plement ETEC vaccine candidates currently in the pipeline to
produce a broadly protective ETEC vaccine that can substan-
tially reduce the diarrheal disease burden in LMIC children.
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